Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2026)

Adaptive Biotechnologies has disclosed Gross Profit across 9 years of filings, most recently posting $52.2 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $52.2 million, up 47.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.3 million (up 101.91% YoY), and the FY2025 annual result was $205.6 million, up 118.28% from the prior year.
• Gross Profit came in at $52.2 million for Q1 2026 at Adaptive Biotechnologies, down from $53.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $75.8 million in Q3 2025 to a low of -$16.2 million in Q2 2023.
• The 5-year median for Gross Profit is $26.3 million (2022), against an average of $30.3 million.
• Across the five-year window, Gross Profit slumped 153.13% in 2023 and surged 241.45% in 2024, its largest moves.
• Adaptive Biotechnologies' Gross Profit stood at $31.5 million in 2022, then gained by 17.22% to $36.9 million in 2023, then retreated by 29.86% to $25.9 million in 2024, then surged by 106.53% to $53.5 million in 2025, then retreated by 2.42% to $52.2 million in 2026.
• The last three Gross Profit figures came in at $52.2 million (Q1 2026), $53.5 million (Q4 2025), and $75.8 million (Q3 2025), per Business Quant data.